GlassScriptPhysician profile
Isaac Kinman
NPI 1265953954
$5,251.99
in general payments reported to CMS, 2019-2025
38 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $236 · 2021: $542 · 2022: $419 · 2023: $979 · 2024: $1,831 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,969.85 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.12 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $473.23 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $381.71 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $360.74 | 2023-2025 | |
| Astellas Pharma US INC | $294.40 | 2020-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.20 | 2021-2025 | Ofev, Jardiance |
| Insulet Corporation | $283.69 | 2023-2025 | Omnipod |
| Pfizer INC. | $274.20 | 2023-2025 | |
| Mannkind Corporation | $253.67 | 2021-2024 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $246.16 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $195.01 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $191.47 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $170.70 | 2022-2023 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $141.07 | 2022-2025 | Shingrix, Arexvy |
| Shield Therapeutics INC | $113.20 | 2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Kinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.